What treatments were used in the case report for ultra-high-risk relapsed Multiple Myeloma?
For ultra-high-risk relapsed multiple myeloma, treatment options are limited and challenging. A recent two-case report evaluated a novel oral combination therapy: ixazomib (a proteasome inhibitor), lisaftoclax (a BCL-2 inhibitor), and dexamethasone (a steroid), given as maintenance after CAR-T cell therapy. This regimen aims to achieve deep and durable disease control, including minimal residual disease (MRD) negativity.
What the research says
The two-case report described two patients with relapsed/refractory ultra-high-risk multiple myeloma who received the ILD regimen (ixazomib 4 mg on days 1, 8, and 15; lisaftoclax 400 mg on days 1-14; and dexamethasone 20 mg on days 1, 8, and 15) in 28-day cycles as maintenance therapy following BCMA-directed CAR-T cell therapy 5. Both patients achieved durable disease control with MRD negativity, suggesting that this combination can optimize MRD eradication and sustain long-term suppression 5. The report noted that all drugs were administered orally, which may offer convenience for patients 5. Other treatments for relapsed multiple myeloma include combinations like carfilzomib, lenalidomide, and dexamethasone (KRd), which has shown efficacy in extramedullary disease 9, as well as approved agents such as selinexor (Xpovio) with bortezomib and dexamethasone 1, lenalidomide (Revlimid) with dexamethasone 3, and pomalidomide (Pomalyst) with dexamethasone 4. However, the specific ILD regimen in this case report represents a novel approach for ultra-high-risk patients after CAR-T therapy.
What to ask your doctor
- Could the ILD regimen (ixazomib, lisaftoclax, dexamethasone) be an option for my situation after CAR-T therapy?
- What are the potential side effects of lisaftoclax, and how are they managed?
- How is MRD negativity monitored, and what does it mean for long-term outcomes?
- Are there other clinical trials or case reports for ultra-high-risk multiple myeloma that might apply to me?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.